CompletedPhase 2NCT01229943
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Studying Neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Matthew H Kulke, MDAlliance for Clinical Trials in Oncology
- Intervention
- Bevacizumab(biological)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2018
Study locations (30)
- Providence Hospital, Mobile, Alabama, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- Kaiser Permanente-Fresno, Fresno, California, United States
- Kaiser Permanente - Harbor City, Harbor City, California, United States
- Kaiser Permanente-Irvine, Irvine, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Kaiser Permanente West Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01229943 on ClinicalTrials.govOther trials for Neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07273409Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or NotUppsala University
- ENROLLING BY INVITATIONPHASE2NCT07121478Patients With High-grade Pancreatic Neuroendocrine TumorsNational Cancer Center, Korea
- RECRUITINGPHASE2, PHASE3NCT06943755Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsExelixis
- RECRUITINGPHASE1NCT06663072Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsUniversity of Chicago
- RECRUITINGPHASE1NCT05687123Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06406387ATRX/DAXX in EUS-FNB Specimens of Pan-NETsAzienda Ospedaliera Universitaria Integrata Verona
- RECRUITINGNCT06121622Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine TumoursIRCCS San Raffaele
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06148636A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine TumorsDavid Bushnell